Richard Elion from Whitman-Walker Health in Washington presented updated 96 week results from the phase 3 head-to-head study of elvitegravir vs raltegravir.1
The 48 week results, first presented at the IAS conference in Rome last year showed elvitegravir to be non-inferior to raltegravir based on viral suppression to <50 copies/mL.2
This phase 3 study randomised 712 treatment-experienced patients to either the investigational integrase inhibitor elvitegravir (150 mg once-daily) or raltegravir (400 mg twice-daily), each with matching placebo, plus a background regimen of a boosted protease inhibitor (PI) plus a third drug.
The primary endpoint of viral load <50 copies/mL through week 48 (time to loss of virologic response [TLOVR] analysis) was achieved by 59% of elvitegravir vs 85% raltegravir patients respectively.
Virological response out to 96 weeks dropped similarly in each arm (to 48% vs 45%%), maintaining non-inferiority for the comparison (difference 2.6; 95%CI -4.6, +9.9). Approximately 40% of patients in each arm discontinued before week 96. Reasons were balanced between arms (non-compliance: 39 vs 34; loss to follow-up: 29 vs 31, lack of efficacy: 17 vs 21, etc) expect for withdrawal of consent (30 vs 17), all elvitegravir vs raltegravir, respectively. The respective percentages of patients with virological failure increased to 26% vs 29% and 26% of patient in each arm had discontinued for other reasons (including side effects). CD4 increases were similar at +205 vs + 195 cells/mm3 (all elvitegravir vs raltegravir, respectively).
Genotypic resistance test results were available for approximately 25% of patients with virological failure in each arm, with a quarter of these in each arm (23/87 vs 26/93) having integrase inhibitor-associated mutations. Although some mutations were shared, elvitegravir was associated with T66I/A (n=8), E92Q/G (n=7), N155H (n=5), T97A (n=4), S147G (n=4) and Q148R (n=4); and raltegravir with N155H (n=16), Q148H (n=7) and T97A (n=4). Resistant mutations associated with NRTIs (3%), PIs (1%) and NNRTIs (2-3%) were similar in each arm. A more detailed analysis of the resistance results was presented as a separate poster.3
Grade 2-4 side effects were similar (68% in each arm) with slightly higher diarrhoea with elvitegravir (13% vs 7%). Limited details were provided for the 20% rate of serious side effects in each group but these only led to discontinuation in 4% vs 3% of patients. Grade 3/4 laboratory abnormalities were also similar, except for slightly higher ALT/AST/GGT in the raltegravir arm (2-3% vs 5-7%).
Elvitegravir has already been submitted to both the to the FDA and EMA for a decision on regulatory approval as a single agent.
Links to other websites are current at date of posting but not maintained.
No comments have been made.
|Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.|